Loading
Cardiometabolic Disease / AMG 513 · Phase 1 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 trial of AMG 513 (a drug candidate for obesity and cardiometabolic disease) designed to evaluate safety and tolerability in 82 participants across single and multiple ascending doses versus placebo. No results have been posted to the registry; the current record describes the study protocol and enrollment status only.
Phase 1, Interventional, Randomized, Sequential, Double masking, Treatment purpose. Cardiometabolic Disease; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Single Ascending Dose (SAD) in Participants with Obesity (P…; Multiple Ascending Dose (MAD) in Participants with Overweig…. Compared with: Placebo. n = 82. 13 sites: United States.
This is a Phase 1 trial of AMG 513 (a drug candidate for obesity and cardiometabolic disease) designed to evaluate safety and tolerability in 82 participants across single and multiple ascending doses versus placebo. No results have been posted to the registry; the current record describes the study protocol and enrollment status only.
No efficacy data; Phase 1 studies are designed for safety and tolerability, not clinical benefit.
The source did not state who this applies to in practice.
This is a Phase 1 safety and tolerability study with no results posted; the registry record describes planned enrollment and endpoints only, without outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06585462). This is a study registration, not published results. Lead sponsor: Amgen. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 82 participants (ACTUAL). Conditions: Cardiometabolic Disease. Interventions: DRUG: AMG 513; DRUG: Placebo; DRUG: AMG 513; DRUG: Placebo. Primary outcome measures: Number of Participants With Treatment-emergent Adverse Events (TEAE) , Day 1 up to approximately 150 days after last dose. Brief summary: The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.